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Mitochondria in neurodegenerative diseases
The mitochondrion consists of 3000 proteins. 3% (about 100 pro‐
teins) among them are responsible for creating 95% ATP needed for 
cells. The remaining 97% of proteins take part in non‐ATP‐related 
functions. Mitochondria have long been known as “energy facto‐
ries,” and now, we are expanding the knowledge from the biology 
and structure of mitochondrion to diseases. In the central nervous 
system (CNS), in addition to ATP production, mitochondrial pro‐
teins are also important for the metabolism of neurotransmitters, 
reactive oxygen species (ROS) production, calcium homeostasis, and 
cell death/survival regulation. The dysfunctional mitochondrion has 
been involved with aging, pain, and neurodegenerative diseases in 
CNS.
Enhancing the biogenesis of functional mitochondria or remov‐
ing dysfunctional mitochondria may be a potential approach to re‐
tard the aging process and treat the related diseases. Yan Wang 
and Erin Xu at University of North Carolina at Chapel Hill, Phillip 
R. Musich at East Tennessee State University, and Fang Lin at 
Soochow University reviewed mitochondrial dysfunction in aging, 
neurodegenerative diseases, and the potential countermeasure.1 
Compounds, which enhance mitochondrial biogenesis, reduce ROS 
levels, and induce mitophagy, would restore mitochondrial homeo‐
stasis in aging and neurodegenerative diseases. Caloric restrict 
and exercise modulate mitochondrial biogenesis, activating mito‐
phagy for removal of damaged mitochondria. Exercise could en‐
hance autophagy‐lysosomal pathway and decrease mitochondrial 
vacuolization caused by chloroquine through restoring autophagic 
flux.2,3
Mitochondrial fission and fusion impact numerous cellular func‐
tions, and neurons are particularly sensitive to perturbations in mito‐
chondrial dynamics. Katrina Cowan, Oleg Anichtchik, and Shouqing 
Luo at Plymouth University highlighted the current knowledge in 
the fundamentals of mitochondrial biology and discussed the mi‐
tochondrion‐related cytotoxicity, mitochondrial fission and fusion 
dynamics, and mitophagy‐mediated mitochondrial quality control.4 
The authors also summarized distinct mitochondrial dysfunctions 
in neurodegenerative diseases, focusing on Parkinson’s disease, 
Huntington’s disease, and Alzheimer’s disease.
Proteins posttranslational modifications including nitrosylation, 
SUMOylation, and phosphorylation regulate the activity and func‐
tion of the protein. Protein kinases and phosphatases can migrate to 
the outer mitochondrial membrane and mediate the signals between 
the mitochondrion and the cell body, and therefore control the 
structure and function of mitochondria. Drp1 translocates from the 
cytosol to the outer mitochondrial membrane to initiate its fission. 
PKA‐mediated phosphorylation of Drp1 inhibits its fission activity, 
whereas dephosphorylation by the Ca2+‐dependent phosphatase 
calcineurin (PP2B) or PP2A activates the enzyme. AKAP1/PKA pro‐
tects against cerebral ischemic stroke by inhibiting Drp1‐dependent 
mitochondrial fission.5 Maribel Lucero, Ana E. Suarez, and Jeremy W. 
Chambers at Florida International University summarized the effects 
of kinases, phosphatases, and the associated adaptor proteins and 
scaffold proteins on the OMM in neurons.6 The authors reviewed 
the roles of specific substrate phosphorylation or dephosphoryla‐
tion events including the impacts on mitochondrial dynamics, cell 
death, fission/fusion, and metabolism. The deficiency in the kinase 
or phosphatase activities associated with the pathophysiology of 
neurological diseases was also discussed.
Dysfunctional mitochondria can be degraded by mitoph‐
agy, which is crucial to maintain mitochondrial healthy. PINK1 
and Parkin have been identified as central players in mitophagy. 
Bingwei Lu’s laboratory at Stanford University recently found that 
OXPHOS mRNAs stalled on the damaged mitochondrial surface to 
form the mRNA‐ribonucleoprotein complex. The cotranslational 
quality control factors Pelo, ABCE1, and NOT4 are recruited to the 
mRNA‐ribonucleoprotein complex, and ABCE1 is ubiquitinated 
by NOT4. As a result, the poly‐Ub‐ABCE1 recruits the autoph‐
agy receptors such as p62, PTEN, and NDP52 to initiate mitoph‐
agy.7 In this issue, Yan Wang and Na Liu at Soochow University 
and Bingwei Lu reviewed the mechanisms of mitophagy in higher 
organisms and the roles of mitophagy in the pathogenesis of 
neurodegenerative diseases.8 Although mitophagy is critical to 
safeguard cell homeostasis, excessive or reduced mitophagy may 
be harmful to cells.
Mitochondria can be transported along and anchored in axons 
and synapses with the change of axonal and synaptic physiology,9 
but the lysosomes mainly locate at the proximity of the nucleus. It 
was puzzling how mitochondria in distal axons are cleared through 
mitophagy. Zhong Chen’s laboratory at Zhejiang University observed 
that axon‐derived mitochondria appeared in neuronal soma and un‐
derwent autophagic clearance. Anchoring of axonal mitochondria by 
syntaphilin blocked neuronal mitophagy and aggravated injury after 
OGD and reperfusion. Conversely, induced binding of mitochondria 
to dynein reinforced retrograde transport and enhanced mitophagy 
to prevent mitochondrial dysfunction and attenuate neuronal injury. 
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Their findings provide a new concept to alleviate ischemic neuronal 
injury by correcting mitochondrial motility.10 In this issue, the au‐
thors, Yanrong Zheng, Xiangnan Zhang, and Zhong Chen, reviewed 
the process of mitochondrial transportation.11 The newly generated 
mitochondria are anterogradely transported from soma to the axon, 
and the damaged mitochondria undergo retrograde transport for 
repair or autophagic clearance. The abnormal transport of mito‐
chondria leads to the accumulation of dysfunctional mitochondria 
and the degeneration of neurons in neurological and psychiatric dis‐
eases. Notably, N‐terminal mutant huntingtin impairs mitochondrial 
trafficking.12 In the meanwhile, endolysosomal deficits result in the 
mitochondrial pathology. Expressing dynein‐adaptor snapin, which 
reverses transport defects and rescues autophagy‐lysosomal defi‐
cits, enhanced mitochondrial turnover and improved the survival of 
motor neurons.13
Recently, J. Marie Hardwick’s laboratory at Johns Hopkins 
University has discovered that KCTD7 mutations lead to the defect 
in autophagy‐lysosomal pathway. Patients with KCTD7 mutations 
exhibit movement disorders or developmental regression before 
seizure onset. The electron microscopy showed abnormal mito‐
chondrial cristae morphologies, lipid droplet accumulation around 
mitochondria, and phagolysosomes containing partially degraded 
material in KCTD7‐mutant patient fibroblasts.14 In this special issue, 
Xinchen Teng at Soochow University, Abdel Aouacheria and Loïc 
Lionnard at Université de Montpellier, and Kyle A. Metz, Lucian 
Soane, Atsushi Kamiya, and J. Marie Hardwick at Johns Hopkins 
University reviewed the biological functions of KCTD family pro‐
teins (such as potential roles in potassium channels and protein 
quality control) and their involvement in neurodevelopmental and 
neuropsychiatric disorders.15 Undoubtedly, the molecular insights 
will facilitate our understanding in the complexity of neurodevelop‐
ment and neurology diseases.
Mitochondrial biology plays an increasingly important role in 
neuroscience research. Over recent years, significant advancement 
has been made in the areas including mitochondrial dynamics, bioen‐
ergetics, fission/fusion, metabolism, and mitophagy. However, more 
biochemical mechanisms, for example in mitochondrial homeostasis 
and mitophagy, yet await elucidation, particularly those relevant to 
mitochondrial diseases and neurodegenerative conditions. The cur‐
rent special issue highlights a few critical advances in the biological 
processes of mitochondria and neurological diseases. Dissemination 
of the knowledge is a necessary step toward the path to uncover‐
ing the enigmas underlying mitochondrial homeostasis and related 
diseases.
Lastly, we would like to thank all the authors, reviewers, and the 
editorial office for their great contributions to this special issue.
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